CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Correctly Ranks Successful Therapy in Metastatic Melanoma Case

CureMatch Correctly Ranks Successful Therapy in Metastatic Melanoma Case
Case Studies

In this case study, a patient with metastatic melanoma was given multiple lines of chemotherapy that were ineffective. The patient’s oncologist subsequently selected a combination of two targeted drugs that led to a remarkable response. This was done “blindly”, i.e., without any genomic sequencing data from the tumor, based on the experience of the oncologist. This retrospective case study shows that the CureMatch platform would have ranked the successful therapy the highest, had genomic data been available. This demonstrates the benefit that the CureMatch platform can provide in guiding oncologists or in providing a second opinion for patients.

Case Study
After failure with standard therapy, a patient with metastatic melanoma started a regimen including a BRAF inhibitor (dabrafenib) in combination with a MEK inhibitor (trametinib). The patient presented a notable response, with a decrease of 34% of the tumor size. The partial response observed with this combination of drugs lasted for more than 11 months, and is considered an exceptional response for metastatic melanoma, for which the 5-year survival rate is about 15% to 20%. The study was published in 2015 in the journal BMC Cancer.

In this case, there was no tissue sample available for testing at diagnosis. Tumor biopsy and molecular profiling was performed 6 months after treatment initiation. Next-generation sequencing of the tumor biopsy revealed, among others, an activating alteration of the oncogene BRAF (BRAF V600E).

Therefore, selection of a BRAF inhibitor (dabrafenib) was the correct decision, but was an “educated guess”, since presence of the BRAF alteration was not certain without tumor profiling data. About half of all melanomas present a BRAF activating mutation, so BRAF inhibitors are often considered as the targeted therapy of choice in this disease, even when a biopsy is not performed. The second agent, a MEK inhibitor (trametinib), was likely selected due to its known ability to reduce acquired resistance, often observed after initiation of treatment with a BRAF inhibitor. However, selection of this combination is not obvious to any oncologist; this regimen was likely chosen by default, after multiple unsuccessful lines of treatment, and these lines may already have induced tumor resistance.

Retrospective Analysis
The CureMatch analysis was retrospectively performed to determine whether CureMatch would have correctly ranked the successful treatment option, using the published tumor profiling data from the patient’s tumor. Next-generation sequencing revealed alterations within BRAF (V600E), NRAS (Q61R), APC (R1171HHH), PTEN (loss) and RB1 (truncation) genes.

A score distribution from the resulting CureMatch analysis is shown in Figure 1, which ranks the likely efficacy of various treatment options using combinations of up to two drugs. The efficacy of the options is ranked by descending Strength Score, a proprietary scoring system developed by CureMatch that analyzes the individual patient’s molecular tumor profile and estimates the best therapeutic agents using proprietary algorithms and manually-curated databases.

Melanoma

Fig. 1. Score Distribution from CureMatch report. All possible combinations of two drugs are represented and ordered by descending strength score. The successful therapy is shown in green, the unsuccessful lines of treatment in red, and other potential options (that could also have been considered) in blue.

 

In the resulting CureMatch report, the combination {dabrafenib + trametinib} was one of the highest-ranked of all of the one- and two-drug combinations considered by the CureMatch platform. This example demonstrates that CureMatch can correctly and automatically predict the top treatment options, without the need for expertise from an oncologist. The CureMatch analysis can be performed in any case when molecular profiling data is available, and can be used to guide the oncologist in the selection of the best therapy, regardless of the experience level of the oncologist.

An additional conclusion can be made: if the patient had received tumor profiling and an optimal therapeutic regimen immediately following the initial diagnosis, multiple ineffective lines of treatment may have been avoided, likely reducing the following:

  • Exposure to unnecessary chemicals and their toxicities
  • Wasted time, during which there was further spread of the disease
  • Cost of unnecessary treatments
  • Drug resistance resulting from unnecessary/unsuitable treatments, which may have affected the efficacy of subsequent combination treatments
  • Negative impacts to the emotional health and quality of life of the patient

The original study was published by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and her colleagues in the journal BMC Cancer. Co-authors on the article were J.J. Wheler, R. Yelensky, G. Falchook, K.B. Kim, P Hwu, A.M. Tsimberidou, P.J. Stephens, D. Hong, and M.T. Cronin. The subsequent retrospective analysis was performed by CureMatch.

 

“Skin!” flickr photo by Quinn Dombrowski shared under a Creative Commons License

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data